SCHEMBL4470450

SCHEMBL4470450

CC(C)Cc1ccc(C(C)C(=O)CC(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 5/20 0.69
CXCR2 P25025 5/20 0.69
PTGS1 P23219 3/20 0.69
PTGS2 P35354 3/20 0.69
LMNA P02545 2/20 0.69
CYP2C9 P11712 2/20 0.69
AKR1C3 P42330 2/20 0.69
ALB P02768 1/20 0.69
ESR1 P03372 1/20 0.69
ALOX5 P09917 1/20 0.69
RARB P10826 1/20 0.69
ADRB3 P13945 1/20 0.69
NFKB1 P19838 1/20 0.69
HTR2A P28223 1/20 0.69
NR1I3 Q14994 1/20 0.69
SLC22A6 Q4U2R8 1/20 0.69
CXCL8 P10145 1/20 0.69
TSHR P16473 1/20 0.69
AKR1C2 P52895 1/20 0.69
BLM P54132 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481095 1.00 CXCR1 (0.69) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4475424 1.00 CXCR1 (0.69) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4483057 0.86 FAAH (0.68) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4483053 0.86 FAAH (0.68) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4481774 0.83 FAAH (0.64) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL6421549 0.83 FAAH (0.64) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4486986 0.83 CXCR1 (0.59) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4486987 0.83 CXCR1 (0.59) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL4481658 0.82 FAAH (0.72) CXCR1CXCR2PTGS1PTGS2LMNA
SCHEMBL13179861 0.82 FAAH (0.72) CXCR1CXCR2PTGS1PTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328057-B2 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases DOMPE' FARMACEUTICI S.P.A. (IT) 2016-05-03 US disclosed
US-20090203652-A1 CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES DOMPE PHA.R.MA S.P.A. (IT) 2009-08-13 US disclosed
EP-1581474-B1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES DOMPE SPA (IT) 2008-08-27 EP disclosed
US-20060247297-A1 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases DOMPE PHA.R.MA S.P.A. (IT) 2006-11-02 US disclosed
EP-1581474-A1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES Dompé S.P.A. (IT) 2005-10-05 EP disclosed
WO-2004052830-A1 CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES DOMPE S.P.A. (IT) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247297-A1 Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases NR1H4, MMP8, NR1I2 CXCR1 392/4885CXCR2 83/4885PTGS1 664/4885
US-20090203652-A1 CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES NR1H4, MMP8, NR1I2 CXCR1 392/4885CXCR2 83/4885PTGS1 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.